Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch

Executive Summary

A Massachusetts court's ruling invalidating a patent on Johnson & Johnson's Remicade (infliximab) appears to clear the way for Pfizer Inc. and Celltrion Inc. to finally launch their FDA-licensed biosimilar Inflectra (infliximab-dyyb). J&J, however, said it plans to appeal and any biosimilar launch would be considered "at risk."

Advertisement

Related Content

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Pfizer/Celltrion Prep For October Inflectra Launch
Stockwatch: Earnings Season Turns Into Silly Season
J&J Thinks It Can Win Over Biosimilar Competition
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel